

16562 U.S. PTO  
08/20/03

Attorney Docket No.: 4796.234-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

03914 U.S. PTO  
10/644187  
08/20/03

Sir:

This is a request for filing a patent application under 37 CFR 1.53(b).

INVENTOR(S)		
First Name	Middle Name	Family Name or Surname
1.Allan 2.Torben 3.Henrik	1. 2.Vedel 3.	1.Svendsen 2.Borchert 3.Bisgard-Frantzen
TITLE OF THE INVENTION		
Alpha-Amylase Mutants		

The following application parts are enclosed:

☒ specification      96 pages      ☐ Sequence Listing 12 pages  
☒ Abstract      1 page      ☐ Formal Drawings 9 pages

The filing fee is calculated as follows:

Basic Fee: \$740.00  
Total Claims:  $20 - 20 = 0 \times 18 =$  \$0.00  
Independent Claims:  $1 - 3 = 0 \times 84 =$  \$0.00  
Total Fee: \$740.00

Priority of Danish application nos. 0515/96, filed on April 30, 1996, 0712/96, filed on June 28, 1996, 0775/96, filed July 11, 1996, 1263/96, filed on November 8, 1996, is claimed under 35 U.S.C. 119(a)-(d).

The benefit of U.S. Application nos. 10/186,042, filed on June 27, 2002, 09/672,459, filed on September 28, 2000 (now a US Patent No. 6,436,888), 09/182,859, filed on October 29, 1998 (now US Patent No. 6,143,708), is claimed under 35 U.S.C. 120.

The benefit of PCT application no. PCT/DK97/00197 filed on April 30, 1997 is claimed under 35 U.S.C. 120.

An application data sheet is enclosed.

This application contains a Sequence Listing. The computer-readable form in this application is identical with that filed in application no. 09/672,459 filed September 28, 2000. In accordance with 37 CFR 1.821(e), please use the last filed computer readable form filed in that application as the computer readable form for the instant application. The content of the attached Sequence Listing and of the computer readable form filed in the parent application is the same.

The assignee of the present application is:

Novozymes A/S  
Krogshoejvej 36  
DK-2880 Bagsvaerd  
Denmark

Applicants request that the assignee information be included in the published patent application.

Direct all correspondence to Customer Number 25908:

PATENT TRADEMARK OFFICE



25908

Please charge the required fee, estimated to be \$740, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: August 20, 2003

Jason I. Garbell, Reg. No. 44,116  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Re: U.S. Patent Application for  
Alpha-Amylase Mutants  
Applicants: Svendsen et al.

Sir:

Express Mail Label No. EV 138339167 US

Date of Deposit: August 20, 2003


I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Application Data Sheet
4. Preliminary Amendment
5. Sequence Listing
6. Information Disclosure Statement
7. Form PTO/SB/08A
8. Executed Declaration

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and to the address indicated above.

Julie Tabarovsky

(Name of person mailing paper(s) or fee)



(Signature of person mailing paper(s) or fee)

Mailing Address:  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097